FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Int J Mol Sci / Gray-Horse Melanoma-A Wolf in Sheep’s Clothing.
International journal of molecular sciences2025; 26(14); 6620; doi: 10.3390/ijms26146620

Gray-Horse Melanoma-A Wolf in Sheep’s Clothing.

Abstract: Malignant melanoma (MM) affects not only humans but also animals, with gray horses being particularly predisposed to acquiring the disease. Multiomics have greatly advanced the understanding of human MM. In contrasty little is known regarding the pathogenesis of gray-horse melanoma and the unique phenomenon of melanoma "dormancy" in some animals. To help close this gap in knowledge, melanoma tissue and intact skin collected from gray horses were subjected to transcriptome analysis using RNAseq. In the next step, cultured primary tumor cells and normal skin fibroblasts were established from gray horses, and their protein expression profiles were determined. The obtained data unambiguously identified gray-horse melanoma (ghM) as a malignant tumor, as reflected by the overrepresentation of pathways typically activated in human melanoma and other human cancers. These included the RAS/RAF/MAPK, the IRS/IGF1R, and the PI3K/AKT signaling networks. In addition, the obtained data suggest that the key molecules RAC1, RAS, and BRAF, which are frequently mutated in human melanoma, may also contain activating mutations in ghM, whilst PTEN may harbor loss-of-function mutations. This issue will be subject to downstream analyses determining the mutational status in ghM to further advance the understanding of this frequent disease in gray horses.
Get Full Text
Publication Date: 2025-07-10 PubMed ID: 40724880PubMed Central: PMC12295847DOI: 10.3390/ijms26146620Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research explores the malignant melanoma (MM) disease in gray horses, and the unique phenomenon of melanoma “dormancy” in these animals. The study used multiomics and transcriptome analysis using RNAseq on melanoma tissue and intact skin from gray horses. The findings suggest that gray-horse melanoma (ghM) share similarities with human melanoma and other human cancers, potentially offering insights for the treatment of both animal and human patients.

Study Objective and Methodology

  • This research was conducted to gain more understanding about the pathogenesis of gray-horse melanoma (ghM) and the unique pattern of melanoma “dormancy” in some animals. The researchers used multiomics, a field integrating data from genomics, proteomics, metabolomics and other -omics to understand complex biological systems.
  • The researchers collected melanoma tissue and intact skin from gray horses for a transcriptome analysis using RNAseq, a methodology used to determine the distinct RNAs within a biological sample at a specific moment. This methodology is particularly useful for identifying the diseases and conditions associated with different RNA patterns.
  • Next, primary tumor cells and normal skin fibroblasts (the most common cells in connective tissue in animals) were cultivated from the gray horses. Their protein expression profiles were then determined, offering information about gene expression and involvement in the disease.

Significant Findings

  • The data derived from the research unambiguously identified gray-horse melanoma (ghM) as a malignant tumor. This conclusion was drawn from the observation of overrepresentation of pathways commonly activated in human melanoma and other human cancers in ghM. These pathways included RAS/RAF/MAPK, IRS/IGF1R, and the PI3K/AKT signaling networks.
  • The data pointed to the possibility that key molecules, including RAC1, RAS, and BRAF (frequently mutated in human melanoma), may also contain activating mutations in ghM. The researchers also speculated that PTEN might harbor loss-of-function mutations in ghM.

Conclusion and Future Research

  • The findings from this study suggest parallels between ghM and human cancers, particularly human melanoma. This opens up the possibility of further research into whether therapies successful in treating human cancers might have a place in treating ghM in horses.
  • The research also identified potential future lines of inquiry, including determining the mutational status in ghM. This work could further increase the understanding of the frequent gray-horse melanoma, potentially informing more targeted and effective treatments for both gray horses and potentially, humans.

Cite This Article

APA
Brodesser DM, Schlangen K, Rodríguez-Rojas A, Kuropka B, Doulidis PG, Brandt S, Pratscher B. (2025). Gray-Horse Melanoma-A Wolf in Sheep’s Clothing. Int J Mol Sci, 26(14), 6620. https://doi.org/10.3390/ijms26146620

Publication

International journal of molecular sciences
ISSN: 1422-0067
NlmUniqueID: 101092791
Country: Switzerland
Language: English
Volume: 26
Issue: 14
PII: 6620

Researcher Affiliations

Brodesser, Daniela M
  • Research Group Oncology (RGO), Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine, Veterinaerplatz 1, 1210 Vienna, Austria.
Schlangen, Karin
  • Section for Biosimulation and Bioinformatics, Centre for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna (MUV), Waehringer Guertel 18-20, 1090 Vienna, Austria.
Rodríguez-Rojas, Alexandro
  • Division of Small Animal Internal Medicine, Department for Small Animals and Horses, University of Veterinary Medicine, Veterinaerplatz 1, 1210 Vienna, Austria.
Kuropka, Benno
  • Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany.
Doulidis, Pavlos G
  • Division of Small Animal Internal Medicine, Department for Small Animals and Horses, University of Veterinary Medicine, Veterinaerplatz 1, 1210 Vienna, Austria.
Brandt, Sabine
  • Research Group Oncology (RGO), Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine, Veterinaerplatz 1, 1210 Vienna, Austria.
Pratscher, Barbara
  • Division of Small Animal Internal Medicine, Department for Small Animals and Horses, University of Veterinary Medicine, Veterinaerplatz 1, 1210 Vienna, Austria.

MeSH Terms

  • Animals
  • Melanoma / genetics
  • Melanoma / veterinary
  • Melanoma / metabolism
  • Melanoma / pathology
  • Horses
  • Skin Neoplasms / genetics
  • Skin Neoplasms / veterinary
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Signal Transduction
  • Horse Diseases / genetics
  • Horse Diseases / metabolism
  • Horse Diseases / pathology
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Gene Expression Profiling
  • Transcriptome
  • Mutation

Grant Funding

  • 2012 / Vienna's Spanish Riding School

Conflict of Interest Statement

The authors declare no conflicts of interest.

References

This article includes 56 references
  1. Berwick M, Buller D.B, Cust A, Gallagher R, Lee T.K, Meyskens F, Pandey S, Thomas N.E, Veierod M.B, Ward S. Melanoma Epidemiology and Prevention. Cancer Treat. Res. 2016;167:17–49.
    doi: 10.1007/978-3-319-22539-5_2pubmed: 26601858google scholar: lookup
  2. Butler A.P, Trono D, Beard R, Fraijo R, Nairn R.S. Melanoma susceptibility and cell cycle genes in Xiphophorus hybrids. Mol. Carcinog. 2007;46:685–691.
    doi: 10.1002/mc.20343pubmed: 17477382google scholar: lookup
  3. Müller S, Wanke R, Distl O. Inheritance of melanocytic lesions and their association with the white colour phenotype in miniature swine. J. Anim. Breed. Genet. 2001;118:275–283.
    doi: 10.1046/j.1439-0388.2001.00280.xgoogle scholar: lookup
  4. Bourneuf E. The MeLiM Minipig: An Original Spontaneous Model to Explore Cutaneous Melanoma Genetic Basis. Front. Genet. 2017;8:146.
    doi: 10.3389/fgene.2017.00146pmc: PMC5645500pubmed: 29081790google scholar: lookup
  5. Scott D.W, Miller W.H.J. Melanoma. 2nd ed. Elsevier Saunders; Maryland Heights, MO, USA: 2011; pp. 506–508.
  6. Seltenhammer M.H, Simhofer H, Scherzer S, Zechner R, Curik I, Solkner J, Brandt S.M, Jansen B, Pehamberger H, Eisenmenger E. Equine melanoma in a population of 296 grey Lipizzaner horses. Equine Vet. J. 2003;35:153–157.
    doi: 10.2746/042516403776114234pubmed: 12638791google scholar: lookup
  7. Valentine B.A. Equine melanocytic tumors: A retrospective study of 53 horses (1988 to 1991). J. Vet. Intern. Med. 1995;9:291–297.
    doi: 10.1111/j.1939-1676.1995.tb01087.xpubmed: 8531173google scholar: lookup
  8. Rosengren Pielberg G, Golovko A, Sundstrom E, Curik I, Lennartsson J, Seltenhammer M.H, Druml T, Binns M, Fitzsimmons C, Lindgren G. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat. Genet. 2008;40:1004–1009.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  9. Sundstrom E, Imsland F, Mikko S, Wade C, Sigurdsson S, Pielberg G.R, Golovko A, Curik I, Seltenhammer M.H, Solkner J. Copy number expansion of the STX17 duplication in melanoma tissue from Grey horses. BMC Genom. 2012;13:365.
    doi: 10.1186/1471-2164-13-365pmc: PMC3443021pubmed: 22857264google scholar: lookup
  10. Curik I, Druml T, Seltenhammer M, Sundstrom E, Pielberg G.R, Andersson L, Solkner J. Complex inheritance of melanoma and pigmentation of coat and skin in Grey horses. PLoS Genet. 2013;9:e1003248.
    doi: 10.1371/journal.pgen.1003248pmc: PMC3567150pubmed: 23408897google scholar: lookup
  11. Hollis A.R. Equine Melanoma Updates. Vet. Clin. N. Am. Equine Pract. 2024;40:431–439.
    doi: 10.1016/j.cveq.2024.07.008pubmed: 39266414google scholar: lookup
  12. Brodesser D.M, Kummer S, Eichberger J.A, Schlangen K, Corteggio A, Borzacchiello G, Bertram C.A, Brandt S, Pratscher B. Deregulation of Metalloproteinase Expression in Gray Horse Melanoma Ex Vivo and In Vitro. Cells 2024;13:956.
    doi: 10.3390/cells13110956pmc: PMC11172212pubmed: 38891088google scholar: lookup
  13. Pozniak J, Marine J.C. Decoding melanoma’s cellular mosaic to unlock immunotherapy potential. Trends Cell Biol. 2025.
    doi: 10.1016/j.tcb.2025.01.009pubmed: 40023663google scholar: lookup
  14. Dongre A, Weinberg R.A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2019;20:69–84.
    doi: 10.1038/s41580-018-0080-4pubmed: 30459476google scholar: lookup
  15. Mani S.A, Guo W, Liao M.J, Eaton E.N, Ayyanan A, Zhou A.Y, Brooks M, Reinhard F, Zhang C.C, Shipitsin M. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–715.
    doi: 10.1016/j.cell.2008.03.027pmc: PMC2728032pubmed: 18485877google scholar: lookup
  16. Pearlman R.L, Montes de Oca M.K, Pal H.C, Afaq F. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Lett. 2017;391:125–140.
    doi: 10.1016/j.canlet.2017.01.029pmc: PMC5371401pubmed: 28131904google scholar: lookup
  17. Thiery J.P, Acloque H, Huang R.Y, Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871–890.
    doi: 10.1016/j.cell.2009.11.007pubmed: 19945376google scholar: lookup
  18. Xiao D, Barry S, Kmetz D, Egger M, Pan J, Rai S.N, Qu J, McMasters K.M, Hao H. Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. Cancer Lett. 2016;376:318–327.
    doi: 10.1016/j.canlet.2016.03.050pmc: PMC4869527pubmed: 27063098google scholar: lookup
  19. Kumar D, Gorain M, Kundu G, Kundu G.C. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma. Mol. Cancer. 2017;16:7.
    doi: 10.1186/s12943-016-0578-3pmc: PMC5282877pubmed: 28137308google scholar: lookup
  20. Marzagalli M, Raimondi M, Fontana F, Montagnani Marelli M, Moretti R.M, Limonta P. Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. Semin. Cancer Biol. 2019;59:221–235.
    doi: 10.1016/j.semcancer.2019.06.019pubmed: 31265892google scholar: lookup
  21. Maniotis A.J, Folberg R, Hess A, Seftor E.A, Gardner L.M, Pe’er J, Trent J.M, Meltzer P.S, Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am. J. Pathol. 1999;155:739–752.
    doi: 10.1016/S0002-9440(10)65173-5pmc: PMC1866899pubmed: 10487832google scholar: lookup
  22. Hendrix M.J, Seftor E.A, Hess A.R, Seftor R.E. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat. Rev. Cancer. 2003;3:411–421.
    doi: 10.1038/nrc1092pubmed: 12778131google scholar: lookup
  23. Hendrix M.J, Seftor E.A, Seftor R.E, Chao J.T, Chien D.S, Chu Y.W. Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. Pharmacol. Ther. 2016;159:83–92.
    doi: 10.1016/j.pharmthera.2016.01.006pmc: PMC4779708pubmed: 26808163google scholar: lookup
  24. Lugassy C, Zadran S, Bentolila L.A, Wadehra M, Prakash R, Carmichael S.T, Kleinman H.K, Peault B, Larue L, Barnhill R.L. Angiotropism, pericytic mimicry and extravascular migratory metastasis in melanoma: An alternative to intravascular cancer dissemination. Cancer Microenviron. 2014;7:139–152.
    doi: 10.1007/s12307-014-0156-4pmc: PMC4275501pubmed: 25304454google scholar: lookup
  25. Yang J.P, Liao Y.D, Mai D.M, Xie P, Qiang Y.Y, Zheng L.S, Wang M.Y, Mei Y, Meng D.F, Xu L. Tumor vasculogenic mimicry predicts poor prognosis in cancer patients: A meta-analysis. Angiogenesis 2016;19:191–200.
    doi: 10.1007/s10456-016-9500-2pubmed: 26899730google scholar: lookup
  26. Long G.V, Swetter S.M, Menzies A.M, Gershenwald J.E, Scolyer R.A. Cutaneous melanoma. Lancet 2023;402:485–502.
    doi: 10.1016/S0140-6736(23)00821-8pubmed: 37499671google scholar: lookup
  27. Seltenhammer M.H, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, Niebauer G.W. Comparative histopathology of grey-horse-melanoma and human malignant melanoma. Pigment Cell Res. 2004;17:674–681.
    doi: 10.1111/j.1600-0749.2004.00192.xpubmed: 15541026google scholar: lookup
  28. Wang Z, Xu Q, Zhang N, Du X, Xu G, Yan X. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct. Target. Ther. 2020;5:148.
    doi: 10.1038/s41392-020-00259-8pmc: PMC7421905pubmed: 32782280google scholar: lookup
  29. Cannon A.C, Uribe-Alvarez C, Chernoff J. RAC1 as a Therapeutic Target in Malignant Melanoma. Trends Cancer. 2020;6:478–488.
    doi: 10.1016/j.trecan.2020.02.021pmc: PMC7380552pubmed: 32460002google scholar: lookup
  30. Acevedo A, Gonzalez-Billault C. Crosstalk between Rac1-mediated actin regulation and ROS production. Free Radic. Biol. Med. 2018;116:101–113.
    doi: 10.1016/j.freeradbiomed.2018.01.008pubmed: 29330095google scholar: lookup
  31. Cannon C.M, Trembley J.H, Kren B.T, Unger G.M, O’Sullivan M.G, Cornax I, Modiano J.F, Ahmed K. Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer. Hum. Gene Ther. Clin. Dev. 2017;28:80–86.
    doi: 10.1089/humc.2017.008pmc: PMC5510041pubmed: 28335614google scholar: lookup
  32. Shaverdashvili K, Wong P, Ma J, Zhang K, Osman I, Bedogni B. MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1. Pigment Cell Melanoma Res. 2014;27:287–296.
    doi: 10.1111/pcmr.12201pubmed: 24387669google scholar: lookup
  33. Zamolo G, Grahovac M, Zauhar G, Vucinic D, Kovac L, Brajenic N, Grahovac B. Matrix metalloproteinases MMP-1, MMP-2, and MMP-13 are overexpressed in primary nodular melanoma. J. Cutan. Pathol. 2020;47:139–145.
    doi: 10.1111/cup.13603pubmed: 31677173google scholar: lookup
  34. Zigrino P, Kuhn I, Bauerle T, Zamek J, Fox J.W, Neumann S, Licht A, Schorpp-Kistner M, Angel P, Mauch C. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J. Investig. Dermatol. 2009;129:2686–2693.
    doi: 10.1038/jid.2009.130pubmed: 19516266google scholar: lookup
  35. Moro N, Mauch C, Zigrino P. Metalloproteinases in melanoma. Eur. J. Cell Biol. 2014;93:23–29.
    doi: 10.1016/j.ejcb.2014.01.002pubmed: 24530009google scholar: lookup
  36. Yang J, Weinberg R.A. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell. 2008;14:818–829.
    doi: 10.1016/j.devcel.2008.05.009pubmed: 18539112google scholar: lookup
  37. Hodis E, Watson I.R, Kryukov G.V, Arold S.T, Imielinski M, Theurillat J.P, Nickerson E, Auclair D, Li L, Place C. A landscape of driver mutations in melanoma. Cell. 2012;150:251–263.
    doi: 10.1016/j.cell.2012.06.024pmc: PMC3600117pubmed: 22817889google scholar: lookup
  38. Yeh I, Bastian B.C. Melanoma pathology: New approaches and classification. Br. J. Dermatol. 2021;185:282–293.
    doi: 10.1111/bjd.20427pmc: PMC9292921pubmed: 34060071google scholar: lookup
  39. Tschandl P, Berghoff A.S, Preusser M, Burgstaller-Muehlbacher S, Pehamberger H, Okamoto I, Kittler H. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS ONE. 2013;8:e69639.
    doi: 10.1371/journal.pone.0069639pmc: PMC3704624pubmed: 23861977google scholar: lookup
  40. Petiot A, Conti F.J, Grose R, Revest J.M, Hodivala-Dilke K.M, Dickson C. A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning. Development. 2003;130:5493–5501.
    doi: 10.1242/dev.00788pubmed: 14530295google scholar: lookup
  41. Hertzler-Schaefer K, Mathew G, Somani A.K, Tholpady S, Kadakia M.P, Chen Y, Spandau D.F, Zhang X. Pten loss induces autocrine FGF signaling to promote skin tumorigenesis. Cell Rep. 2014;6:818–826.
    doi: 10.1016/j.celrep.2014.01.045pmc: PMC4080841pubmed: 24582960google scholar: lookup
  42. Grose R, Fantl V, Werner S, Chioni A.M, Jarosz M, Rudling R, Cross B, Hart I.R, Dickson C. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 2007;26:1268–1278.
    doi: 10.1038/sj.emboj.7601583pmc: PMC1817631pubmed: 17304214google scholar: lookup
  43. Goyal L, Saha S.K, Liu L.Y, Siravegna G, Leshchiner I, Ahronian L.G, Lennerz J.K, Vu P, Deshpande V, Kambadakone A. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017;7:252–263.
    doi: 10.1158/2159-8290.CD-16-1000pmc: PMC5433349pubmed: 28034880google scholar: lookup
  44. Gartside M.G, Chen H, Ibrahimi O.A, Byron S.A, Curtis A.V, Wellens C.L, Bengston A, Yudt L.M, Eliseenkova A.V, Ma J. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 2009;7:41–54.
    doi: 10.1158/1541-7786.MCR-08-0021pmc: PMC4233648pubmed: 19147536google scholar: lookup
  45. Cismas S, Pasca S, Crudden C, Trocoli Drakensjo I, Suleymanova N, Zhang S, Gebhard B, Song D, Neo S, Shibano T. Competing Engagement of beta-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness. Mol. Cancer Res. 2023;21:1288–1302.
    doi: 10.1158/1541-7786.MCR-22-0871pubmed: 37584671google scholar: lookup
  46. Lee J.T, Brafford P, Herlyn M. Unraveling the mysteries of IGF-1 signaling in melanoma. J. Investig. Dermatol. 2008;128:1358–1360.
    doi: 10.1038/jid.2008.124pubmed: 18478012google scholar: lookup
  47. Davies M.A. The role of the PI3K-AKT pathway in melanoma. Cancer J. 2012;18:142–147.
    doi: 10.1097/PPO.0b013e31824d448cpubmed: 22453015google scholar: lookup
  48. Brodesser D.M, Schlangen K, Burgstaller J, Brandt S, Pratscher B. Expression signature of grey horse melanoma; Proceedings of the ESVONC, European Society of Veterinary Oncology Annual Congress; Lyon, France. 18–22 April 2017.
  49. Wade C.M, Giulotto E, Sigurdsson S, Zoli M, Gnerre S, Imsland F, Lear T.L, Adelson D.L, Bailey E, Bellone R.R. Genome sequence, comparative analysis, and population genetics of the domestic horse. Science 2009;326:865–867.
    doi: 10.1126/science.1178158pmc: PMC3785132pubmed: 19892987google scholar: lookup
  50. Li R, Yu C, Li Y, Lam T.W, Yiu S.M, Kristiansen K, Wang J. SOAP2: An improved ultrafast tool for short read alignment. Bioinformatics 2009;25:1966–1967.
    doi: 10.1093/bioinformatics/btp336pubmed: 19497933google scholar: lookup
  51. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav. Brain Res. 2001;125:279–284.
    doi: 10.1016/S0166-4328(01)00297-2pubmed: 11682119google scholar: lookup
  52. Fabregat A, Sidiropoulos K, Viteri G, Forner O, Marin-Garcia P, Arnau V, D’Eustachio P, Stein L, Hermjakob H. Reactome pathway analysis: A high-performance in-memory approach. BMC Bioinform. 2017;18:142.
    doi: 10.1186/s12859-017-1559-2pmc: PMC5333408pubmed: 28249561google scholar: lookup
  53. Hainisch E.K, Jindra C, Reicher P, Miglinci L, Brodesser D.M, Brandt S. Bovine Papillomavirus Type 1 or 2 Virion-Infected Primary Fibroblasts Constitute a Near-Natural Equine Sarcoid Model. Viruses 2022;14:2658.
    doi: 10.3390/v14122658pmc: PMC9781842pubmed: 36560661google scholar: lookup
  54. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2007;2:1896–1906.
    doi: 10.1038/nprot.2007.261pubmed: 17703201google scholar: lookup
  55. Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 2016;11:2301–2319.
    doi: 10.1038/nprot.2016.136pubmed: 27809316google scholar: lookup
  56. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein M.Y, Geiger T, Mann M, Cox J. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods. 2016;13:731–740.
    doi: 10.1038/nmeth.3901pubmed: 27348712google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.